

25. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 2003; 111:1201–1209.
26. Saadjian A, Philip-Joet F, Paganelli F, Arnaud A, Levy S. Long-term effects of cicletanine on secondary pulmonary hypertension. *J Cardiovasc Pharmacol* 1998; 31:364–371.
27. Toshner M, Voswinckel R, Southwood M, et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2009; 180:780–787.
28. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. *Eur Respir J* 2010; 36:792–799.
29. Ghofrani HA, Voswinckel R, Gall H, et al. Riociguat for pulmonary hypertension. *Future Cardiol* 2010; 6:155–166.
30. Schmidt HH, Schmidt PM, Stasch JP. NO- and Haem-independent soluble guanylate cyclase activators. *Handb Exp Pharmacol* 2009; 191:309–339.
31. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. *Handb Exp Pharmacol* 2009; 191:277–308.
32. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. *Eur Respir J* 2010; 36:792–799.
33. Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. *Circulation* 2009; 119:2781–2788.
34. Clinicaltrials.gov Identifier: NTC01065454
35. Clinicaltrials.gov
36. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. *Thorax* 2006; 61:736.
37. Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. *Transplant Proc* 2009; 41:1969–1971.
38. Gomberg-Maitland M, Maitland ML, et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. *Clin Pharmacol Ther* 2010; 87:303–310.
39. Mouchaers KT, Schaliij I, de Boer MA, et al. Effective reduction of MCT-PAH by Fasudil. Comparison with bosentan and sildenafil. *Eur Respir J* 2010; 36:800–807.
40. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. *Circ J* 2006; 70:174–178.
41. Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. *Heart Vessels* 2010; 25:144–149.
42. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. *Circulation* 2002; 105:1672–1678.
43. Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. *Circ Res* 2005; 96:1053–1063.
44. Sobolewski A, Rudarakanchana N, Upton PD, et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. *Hum Mol Genet* 2008; 17:3180–3190.
45. Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine_{2A} receptor and transporter. *Am J Respir Crit Care Med* 2004; 170:252–259.
46. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. *Chest* 1992; 102:1407–1412.
47. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. *Am J Respir Crit Care Med* 2009; 179:1048–1054.
48. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. *Am J Physiol Heart Circ Physiol* 2003 285:H938–H945

IMAGES IN CARDIOLOGY

Catheter Ablation of Incessant Ventricular Tachycardia in a Patient With Coronary Artery Disease

Konstantinos P. Letsas, MD, Michael Efremidis, MD, Antonios Sideris, MD

Second Department of Cardiology, Evagelismos General Hospital of Athens, Greece.

A 67-year-old male with known coronary artery disease was referred to our hospital for catheter ablation of incessant ventricular tachycardia (VT). Transthoracic echocardiography revealed severe wall motion abnormalities of the left ventricle along with an apical aneurysm. Left ventricular voltage mapping showed a region with low voltage (<1.5 mV) at the left ventricular apex. Propagation mapping revealed a macro-reentry circuit around the apical aneurysm. Mid-diastolic potentials were recorded during the VT (**Fig. 1**, left panel, arrows), while entrainment mapping was excellent. The first radiofrequency energy application terminated the tachycardia. A circumferential lesion around the aneurysm was finally performed (**Fig. 1**, right panel, red dots). Ventricular tachycardia became non-inducible, and the patient is free from arrhythmic events during the last six months.




Figure 1. Surface ECG and intracardiac electrograms are depicted on the left panel and electroanatomical mapping on the right panel (see text for discussion)

Cardiology News /Recent Literature Review

Ector Anninos, MD, Spyridon Koulouris, MD, Antonis S. Manolis, MD

The **TCT** Annual Conference will be held in San Francisco 7-11/11/2011

The **AHA** Annual Scientific Sessions are scheduled for 12-16/11/2011 in Orlando

The next **ACC** Annual Meeting is slated for 24-27/3/2012 in Chicago

The **Athens Cardiology Update 2012** is slated for April 5-7, 2012

The **HRS 33rd** Annual Meeting will be held in Boston, 9-12/5/2012

The next **ESC** Annual Congress will be held in Munich, 25-29/8/2012

Incidence and Predictors of ICD Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy (ARVC) Undergoing ICD Implantation for Primary Prevention

Eighty-four patients with definite or probable ARVC underwent ICD implantation for primary prevention. After a follow-up of 4.7 ± 3.4 years, appropriate ICD therapy was delivered in 40 patients (48%). Predictors of such an intervention were proband status ($p < 0.001$), inducibility at electrophysiologic study ($p = 0.005$), presence of nonsustained ventricular tachycardia ($p < 0.001$), and Holter premature ventricular complex count $>1,000/24$ h ($p = 0.024$). In multivariate analysis,

inducibility at electrophysiologic study and nonsustained ventricular tachycardia remained significant predictors. The number of these risk factors correlates with the incidence of ICD activation with the 5-year survival free of appropriate ICD therapy for patients with 1, 2, 3, and 4 risk factors being 100%, 83%, 21%, and 15%, respectively (Bhonsale A et al, *J Am Coll Cardiol* 2011; 58:1485-1496).

Exclusion of the Left Atrial Appendage with a Novel Device: Early Results of a Multicenter Trial

Seventy patients with atrial fibrillation or a CHADS₂ score greater than 2 undergoing elective cardiac surgery were eligible for concomitant AtriClip device (35, 40, 45, and 50 mm) insertion. Safety was assessed at 30 days, and efficacy of left atrial appendage exclusion was assessed at operation (by transesophageal echocardiography) and at 3-month follow-up (by computed tomography angiography or transesophageal echocardiography). Intraprocedural success reached 95.7% (67 of 70 patients). Although significant adverse events occurred in 34 of 70 patients (48.6%), none was related to the device and there was no perioperative mortality. At 3-month follow-up, 98.4% of the patients had successful left atrial appendage exclusion by computed tomography angiography or transesophageal echocardiography imaging (Ailawadi G et al, *J Thorac Cardiovasc Surg* 2011; 142:1002-1009).

SCN5A Mutations Associate With Arrhythmic Dilated Cardiomyopathy and Commonly Localize to the Voltage-Sensing Mechanism

In this study the role of the cardiac sodium ion channel SCN5A in the etiology of dilated cardiomyopathy (DCM) was examined. To achieve this, DNA samples from 338 individuals among 289 DCM families were screened for SCN5A mutations by sequence analysis. The authors identified 5 missense SCN5A mutations representing the 1.7% of DCM families. Three of these mutations are novel (E446K, F1520L, and V1279I) and two are already known ones (D1275N and R222Q). In the majority of the cases the mutation was located to the highly conserved homologous S3 and S4 transmembrane segments, suggesting the disruption of the voltage-sensing mechanism of this sodium channel as the underlying mechanism leading to DCM. Most of the SCN5A mutation carriers manifested supraventricular arrhythmia (13/15), sick sinus syndrome (5/15) atrial fibrillation (9/15), ventricular tachycardia (5/15), and conduction disease (9/15) (McNair WP et al, *J Am Coll Cardiol* 2011;57: 2160-2168.)